Showing 4071-4080 of 6805 results for "".
- Study Highlights Unique Characteristics of Melanoma Patients Who Use Tanning Bedshttps://practicaldermatology.com/news/study-highlights-unique-characteristics-of-melanoma-patients-who-use-tanning-beds/2457509/Younger individuals and females are more likely to use tanning beds, and as a result they tend to develop melanoma earlier, according to
- The American Dermatological Association Is On Board with American Cancer Society's HPV Vaccine Policyhttps://practicaldermatology.com/news/the-american-dermatological-association-is-on-board-with-american-cancer-societys-hpv-vaccine-policy/2457513/The American Dermatological Association is co-sponsoring the American Cancer Society’s public policy of vaccination against Human Papillomavirus infections [HPV] beginning at age 11 or 12 for girls and boys. HPV is associated with protean medical illne
- Endo's CCH Improves Appearance of Cellulite in Buttockshttps://practicaldermatology.com/news/endos-cch-improves-appearance-of-cellulite-in-buttocks/2457516/Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment,
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infectionshttps://practicaldermatology.com/news/la-biomed-team-to-study-treatments-for-antibiotic-resistant-skin-infections/2457533/Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study,
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder
- Topix Pharmaceuticals Introduces Its New Backbar Linehttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-its-new-backbar-line/2457572/Topix Pharmaceuticals, Inc. is rolling out its Backbar Line, a collection of 10 professional products that allows physicians to use their own branding. Only available for sale direct to office, the line is designed to support procedures and non-i
- Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis/2457575/The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate i